Du är här


Pluristem Therapeutics Inc.: Pluristem & Charite Expand Cooperation Agreement to Include Orthopedic Indications

HAIFA, Israel, Oct. 13, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy
products, today announced it has expanded itsfive-year Collaborative Research
Agreement with the Berlin-Brandenburg Center for Regenerative Therapy at
Charité - University Medicine Berlin. The expanded agreement, which was
executed on October 11that the Berlin-Tel Aviv Business Forum in Tel Aviv,
broadens the parties' cooperation to include identification of orthopedic
indications that may be eligible for development under Europe's Adaptive
Pathways and conditional marketing approval in the European Union.
Pluristem's program to develop PLX cells in critical limb ischemia is already
under discussion with the EMA and other European Stakeholders under the
Adaptive Pathways.

Under the five-year Collaborative Research Agreement, Pluristem and Charité
have jointly completed a successful orthopedic Phase I/II study using
PLacental eXpanded (PLX) cells in muscle injury. The parties have also
collaborated on a variety of other indications, including kidney diseases
such as acute kidney injury, cardiovascular indications such as inflammatory
cardiomyopathy, and comprehensive immunological research for Pluristem's
Peripheral Artery Disease clinical programs.

Dr. Tobias Winkler of the Center for Musculoskeletal Surgery&Julius Wolff
Institute Berlin, Charité, who served as Senior Scientist on the completed
Phase I/II orthopedic study, commented, "In our studies PLX cells
demonstrated the potential to improve overall muscle functionality, with an
impressive magnitude of effect. An additional orthopedic PLX indication has a
promising potential."

"Pluristem has enjoyed a very productive relationship with European regulators
and our PLX cells have already been selected for the Adaptive Pathways in
critical limb ischemia. Working with the prestigious Charité, we look forward
to advancing an orthopedic indication through Adaptive Pathways as well,"
stated Pluristem Chairman and CEO, Zami Aberman.

About BCRT

The Berlin-Brandenburg Center for Regenerative Therapies was founded as a
cooperative research institution of the Charité University Hospital in Berlin
and Germany's largest research association, the Helmholtz Association. The
mission of the BCRT is to develop a translational platform for Regenerative
Therapies from bench-to-bedside. The five clinical platforms-Immune,
musculoskeletal, hepatic, neuronal, and cardiovascular system-are
cross-linked by technology platforms (basic science, bio-engineering,
translational technologies).

About Adaptive Pathways

The purpose of Europe's Adaptive Pathways is to shorten the time it takes for
innovative medicines to reach patients with serious conditions that lack
adequate treatment options. The pathway is open to clinical programs in early
stages of development only. After a therapy is selected for the program, the
Adaptive Pathways Discussion Group provides detailed guidance to the
applicant previous to the formal regulatory processes that precede a trial
targeting early or conditional approval and further expansion of the

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapy products. The Company has reported robust clinical trial data in
multiple indications for its patented PLX (PLacental eXpanded) cells. The
cells release a cocktail of therapeutic proteins in response to inflammation,
ischemia, hematological disorders, and radiation damage. PLX cell products
are grown using the Company's proprietary three-dimensional expansion
technology. They are off-the-shelf, requiring no tissue matching prior to

Pluristem has a strong intellectual property position; Company-owned,
GMP-certified manufacturing and research facilities; strategic relationships
with major research institutions; and a seasoned management team.

For Safe Harbor Statement please visit

Pluristem Therapeutics Inc.
Karine Kleinhaus, MD, MPH
Divisional VP, North America


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Pluristem Therapeutics Inc. via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.